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Abstract Vitamin B6 metabolites and their potential
correlates to urinary oxalate excretion in idiopathic
calcium stone formers (ICSF) compared with healthy
subjects were investigated. This clinical study was
performed in a population of male ICSF with (Hyper-
oxalurics, n=55) or without hyperoxaluria (Normoox-
alurics, n=57) as well as in 100 healthy male control
subjects. Pyridoxal 5-phosphate serum concentration
(S-pyridoxal 5P) and 24-h urinary excretion of 4-pyri-
doxic acid (U-4pyridoxic acid) were measured using
HPLC; 24-h urinary excretion of oxalate (U-oxalate)
was measured concurrently. A subgroup of subjects (40
Hyperoxalurics, 15 Normooxalurics and 50 controls)
underwent the same measurements before and after 7-
day pyridoxine loading per os (pyridoxine hydrochlo-
ride, 300 mg/d). Under usual conditions, U-4pyridoxic
acid was similar in the three groups, whereas mean
S-pyridoxal 5P was significantly lower (p<0.0001) in
the Hyperoxalurics (59.6±21.2 nmol/L) and in the
Normooxalurics (64.9± 19.7 nmol/L) than in the
controls (86.0±31.0 nmol/L). No correlation could be
found between U-oxalate and U-4pyridoxic acid or
S-pyridoxal 5P. After B6 loading, S-pyridoxal 5P was
still significantly lower in the Hyperoxalurics
(415±180 nmol/L, p<0.001) and in the Normoox-
alurics (429±115 nmol/L, p=0.036) than in the controls
(546±180 nmol/L), although there was no difference
between groups for U-4pyridoxic acid. No correlation in
any group could be found between changes in U-oxalate
and changes in U-4pyridoxic acid or S-pyridoxal 5P.
Although there is no vitamin B6 deficiency in ICSF with
or without hyperoxaluria, these patients, on average,
have lower levels of S-pyridoxal 5P than healthy sub-
jects. However, this slight decrease does not seem to
account for idiopathic hyperoxaluria.
Keywords Nephrolithiasis Æ Pyridoxin Æ
Hyperoxaluria
Introduction
Nephrolithiasis is a common medical problem, affecting
5–10% of the western population over lifetime [1].
Eighty to 90% of stones are composed of calcium salts,
mainly calcium oxalate monohydrate (whewellite), cal-
cium oxalate dihydrate (weddellite) and less commonly
calcium phosphate [1]. Idiopathic stone disease is char-
acterized by recurrent formation of calcium oxalate or
calcium phosphate stones without any apparent under-
lying cause.
The origin of so-called idiopathic hyperoxaluria
is still unclear. Mild to moderate hyperoxaluria (450–
670 lmol/24 h) may result from consumption of
oxalate-rich food (spinach, nuts, chocolate) [1]. The
absorption of oxalate is highly variable between indi-
viduals and can contribute up to 52.6±8.6% of urinary
oxalate [2] depending, for example, on the concurrent
calcium content of the diet. The major part, however, is
believed to have a metabolic origin (e.g., from meat
protein), which may be either direct from tryptophan or
indirect from hydroxyproline via glyoxylate. The latter
is to a large extent transaminated into glycine, thus
preventing excessive production of oxalate (Fig. 1).
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This transamination requires vitamin B6 as a cofactor
in the alanine-glyoxylate transaminase enzyme pathway
[3]. It is well established that nutritional pyridoxine
deficiency leads to a marked increase in urinary oxalate
excretion in rats [4] and to the production of urinary
calculi [4]. Several studies both in animals [5] and in
man [6, 7] suggest that pyridoxine and magnesium may
prevent calcium oxalate urolithiasis and that pyridoxine
administration leads to a decrease in urinary oxalate
in patients with recurrent urolithiasis [8, 9] and in
about 30% of patients with primary hyperoxaluria
[10, 11, 12].
It is generally accepted that excessive intake of meat
protein or oxalate, as well as insufficient hydration,
confers a significant risk of renal stone formation,
whereas the effect of intake of vegetable fibers has been
a matter of debate for a long time [13, 14]. Data
gleaned after World War II revealed that when a
country undergoes protein deprivation, the prevalence
of renal stones decreases, whereas the converse is true
when protein intake resumes. Excessive ingestion of
animal protein (meat, poultry and fish) also leads to an
increase in urinary uric acid and calcium and to a de-
crease in urinary pH and citrate. These changes in-
crease the risk of idiopathic calcium urolithiasis. Some
patients, but not all, even develop mild hyperoxaluria
on high protein intake, which may be due to the fact
that vitamin B6 requirement increases with dietary
protein intake [15].
The present study has been designed to look for
alterations of vitamin B6 metabolites and their poten-
tial link to urinary oxalate excretion in idiopathic
calcium stone formers (ICSF) with or without hyper-
oxaluria compared with healthy subjects taken as
controls.
Methods
A. Cross-sectional study = investigation under
free-choice diet
Calcium stone formers
From 271 consecutive male renal stone formers routinely exam-
ined at our clinic between January 1993 and March 1999, we
selected two populations of idiopathic calcium stone formers
(ICSF) as defined by their urinary oxalate excretion, i.e.:
– ‘‘the Hyperoxalurics’’ ICSF (n=55) with consistent mild hy-
peroxaluria defined by a urinary excretion of oxalate above
450 lmol/day [13] on free-choice diet in at least two of three
urine collections
– ‘‘the Normooxalurics’’ ICSF (n=57) defined by a urinary
excretion of oxalate below 450 lmol/day on a free-choice diet in
all three urine collections
All patients fulfilled the following criteria: (1) they were
Caucasian patients with at least two episodes of renal stones; (2)
they had an examination consisting of a general case history and
a dietary case history focused on past and current intake of dairy
products, oxalate sources, flesh protein, vegetable fibers, salt and
water. Clinical status included body size, body weight, lumbar
palpation, and blood pressure measurement. Classic blood and
urine chemistry profiles were obtained, and any previously per-
formed intravenous pyelography was read for disclosing medul-
lary sponge kidneys; (3) they did not have any established cause
of calcium stone formation such as primary hyperparathyroidism,
renal tubular acidosis, sarcoidosis or primary hyperoxaluria; (4)
they had no history of urinary tract infection or of any renal
disease other than urolithiasis; (5) they had no history of
Fig. 1 Metabolic pathways
from meat protein to oxalate.
Shaded circles correspond to the
various enzyme: AGT Alanine-
glyoxylate aminotransferase,
GR glyoxylate reductase, GO
glycolate oxidase, LDH lactate
dehydrogenase. AGT deficiency
causes type 1 primary
hyperoxaluria, where glyoxylate
cannot be metabolized to
glycine, leading both glycolate
and oxalate to accumulate.
Vitamin B6 supplementation
may partially or completely
correct the metabolic disorder
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gastrointestinal disorders that could affect the intestinal absorp-
tion of vitamin B6; (6) they were not taking any vitamin B6
supplements or medications that might interfere with vitamin B6
metabolism; (7) they had deep-frozen serum samples ()80C); and
(8) they had three 24-h urine collections on a free-choice diet with
frozen samples ()20C).
The stones had been analyzed by infrared spectrophotometry at
our institution in the 55 patients included in the prospective study
and chemically in most of the remaining ones.
From frozen samples 24-h urine was assayed for 4-pyridoxic
acid, the catabolite of B6 and serum for pyridoxal 5 phosphate, the
active moiety of B6.
Healthy subjects
One hundred healthy caucasian male volunteers were recruited for
the study through advertising. The subjects were selected on the
basis of a general and medical history questionnaire. A past history
of renal stone disease in the subject or his parents led to exclusion
from the study.
The subjects were asked to remain on a free-choice diet. No
nutrition diary was obtained. Urine and blood samples were
collected 4 weeks after recruitment.
B. Intervention study = vitamin B6 loading
Among ICSF patients studied cross-sectionally, 55 volunteered to
participate in the vitamin B6 loading study. From those, only 15
had a consistently normal rate of oxalate excretion. In addition,
50 healthy subjects were recruited through advertisement in the
newspapers. They were specifically instructed to refrain from
taking any mineral, vitamin, or protein supplements as well as
sweeteners during the 4 weeks before vitamin B6 treatment. The
subjects were asked to maintain their normal lifestyle and their
usual level of activity and free-choice diet. They were encouraged
to drink at least 2 l of fluid each day. The subjects kept a diary of
tablet intake and potential side effects. The actual pill count was
not performed, but the compliance of both patients and controls
was assessed by measuring the urinary excretion of 4-pyridoxic
acid.
At baseline (day 0), a 24-h urine was collected and a fasting
blood sample was drawn at the end of the urine collection period
(day 1). Pyridoxine supplementation was carried out with one
tablet of 300 mg of pyridoxine hydrochloride (Benadon; Roche
Pharma AG, Reinach, Switzerland) taken daily for 7 days before
breakfast. The subjects collected a second 24-h urine on day 7 (last
day on vitamin B6) and returned to the laboratory in the morning
of day 8 for a second fasting blood sample.
Sample collection and preparation
Urine was collected over 24 h in 3-l plastic bottles containing
10 g of boric acid as preservative. Because of the sensitivity to
light of vitamin B6 derivatives, the subjects were instructed to
store the urine bottle in a dark and cool place during the
collection period. After shaking, urine samples were taken from
each bottle and placed into six 10-ml tubes. Three of them were
acidified with concentrated hydrochloric acid to prevent oxalate
crystallization and conversion of ascorbate to oxalate [3].
Samples were frozen immediately and stored at )20C until
assay.
After a 10-h fast, venous blood samples (approximately 50 ml)
were obtained in the morning after completion of the 24-h urine
collection. Serum and plasma samples were kept from light, frozen
immediately and stored at )80C until assay.
Analytical methods
Urine 4-pyridoxic acid (U-4pyridoxic acid) and serum pyridoxal
5-phosphate (S-pyridoxal 5P) were measured by HPLC with
fluorescence detection. Fluorescence was enhanced through addi-
tion of a post-column buffer containing sodium bisulfite (No. S-
9000; Sigma Chemical, St. Louis, MO). The columns consisted of a
Nova-Pak C18, 4.6·250 mm, with 4-lm particles (WATO52840;
Waters, Rupperswil, Switzerland), a lBondapak C18, 3.9·300 mm,
with 10-lm particles (WATO27324), followed by a RCM 8·10
module with a lBondapak C18 column, 8·100 mm, with 10-lm
particles (WATO85721). For the isocratic eluant, 10 ml of acetic
acid 100% (No. 1.00063; Merck KGaA, Darmstadt, Germany)
were dissolved in 900 ml water. Then, pH was adjusted to 3.20 with
triethylamine 99% and diluted with water to 1 l. Hexanesulfonic
acid (825 mg) was added just before analysis. Samples were mea-
sured by fluorescene with excitation and emission, wavelength
being set at 320 and 420 nm for urine and at 335 and 405 nm for
serum. The recovery of both vitamin B6 metabolites ranged from
97 to 102%. The intraassay coefficient of variation ranged from 3.6
to 6.0% for P5P and from 1.7 to 2.0 for 4PA. The interassay
variation coefficient ranged from 2.9 to 7.7% for P5P and from 6.3
to 6.9% for 4PA.
The plasma and urine concentration of creatinine was mea-
sured using an autoanalyzer. Urine oxalate was measured
according to Buttery et al. [16] using oxalate oxidase and HPLC
in the same assay; glycolate was determined using spinach glycolic
acid oxidase. Urine concentration of urea was measured by using
a kinetic test with urease and glutamate dehydrogenase (Cobas
Integra 700).
Statistics
Statistical analyses were performed with StatView for Windows
(version 5.0.1; SAS Institute, Cary, NC). All the values in the
text, tables and illustrations are presented as mean ± SD.
The normal range for the healthy volunteers was used as the
95% confidence interval. Statistical comparisons were consid-
ered to be significant at P £ 0.05, using non parametric tests,
i.e. Mann-Whitney U test for the comparison between two
groups, Kruskal-Wallis test for comparison among three
groups, Wilcoxon paired test for intragroup after/before com-
parison and the Spearman rank test for correlation between two
parameters.
Ethics
Experimental plans, procedure, and consent forms of the study had
been approved by the Committee for Medical and Ethical Ques-
tions of the University of Berne, and written informed consent was
obtained from each participant.
Results
Cross-sectional study
The composition of renal stone was similar in the nor-
mooxaluric and the hyperoxaluric stone formers. By
definition, U-oxalate was lower in the Normooxalurics
than in the Hyperoxalurics. The control subjects had
intermediate values. The daily urinary output of creati-
nine was higher in both ICSF groups than in the con-
trols and higher in the Hyperoxalurics than in the
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Normooxalurics. U-glycolate was significantly higher in
the Hyperoxalurics and the Normooxalurics than in the
controls, and U-urea was higher in the Hyperoxalurics
than in the controls (see Table 1).
Individual values of U-4pyridoxic acid excretion as
well as S-pyridoxal 5P concentrations are plotted in
Fig. 2. The normal range was 3.5–14.5 lmol/24 h for
U-4 pyridoxic acid excretion and 42–165 nmol/L for
S-pyridoxal 5 P. Although there were no intergroup
differences in terms of U-4 pyridoxic acid excretion,
S-pyridoxal 5P concentrations, on average, were
significantly lower in the NormoOxaluric and Hyper-
oxalurics than in the controls.
U-4pyridoxic acid and S-pyridoxal 5P concentra-
tions correlated positively in the controls and in
Normooxalurics but not in the Hyperoxalurics. In all
three groups U-4 pyridoxic acid was positively corre-
lated with U-urea. In the controls only, there were
weak positive correlations between S-pyridoxal 5P
concentration vs. U-urea, U-4 pyridoxic acid vs. U-
glycolate and U-4pyridoxic acid vs. U-oxalate,
respectively. No correlation in any group could be
found between S-pyridoxal 5P and U-oxalate (see
Table 2).
Pyridoxine loading
Characteristics of the 105 subjects who underwent pyr-
idoxine loading on free-choice diet are presented in
Table 3. After vitamin B6 loading S-pyridoxal 5P was
found elevated far above the normal range. In all three
groups, U-4 pyridoxic acid also increased similarly
among the three groups.
The individual values of vitamin B6 metabolites after
pyridoxine loading are plotted in Fig. 3 showing a large
natural variability. One Hyperoxaluric and one control
subject had U-4pyridoxic acid levels lower than the
other subjects, suggesting either poorer absorption of
pyridoxine or inadequate compliance in the last days of
treatment. After 7 days on vitamin B6, S-pyridoxal 5P
was elevated in all subjects (inclusively in those two
subjects with low U-4pyridoxic acid). The mean post-
loading values of S-pyridoxal 5P were lower in the
Normooxalurics or the Hyperoxalurics than in the
controls.
On average, the urinary excretion rate of oxalate did
not change significantly after pyridoxine loading either
in the controls or in ICSF and there was no correlation
between the changes in oxalate excretion and the
Table 1 Characteristics of the subjects (cross-sectional study)
Group P values
Controls
(n=100)
Normo
Oxalurics
(n=57)
Hyper
Oxalurics
(n=55)
Normo- vs.
Hyper-Oxalurics
Normo-Oxalurics
vs. controls
Hyper-Oxalurics
vs. controls
All three
groups
Age (y) 38.0±10.3 45.8±11.5 44.7±12.7 NS <0.0001 0.0006 <0.0001
Height (m) 1.78±0.07 1.74±0.08 1.75±0.07 NS 0.003 0.006 0.002
Weight (kg) 74.4±10.6 79.1±13.7 82.1±12.0 NS 0.02 <0.0001 0.0002
BMI (kg/m2) 23.4±3.3 25.9±3.5 26.9±3.8 NS <0.0001 <0.0001 <0.0001
Stone Analysis (IR spectro)
Oxalate
monohydrate
‡ 80%
) 15/34 7/23 NS ) ) NS
Other oxalate stones ) 12/34 12/23 NS ) ) NS
Non predominant
Oxalate
) 7/34 4/23 NS ) ) NS
Urine parameters
U-Volume (ml) 1843±752 1737±726 2313±813 <0.0001 NS 0.0006 0.0001
U-Creatinine
(lmol/d)
14000±2650 15159±3504 17043±4060 0.03 0.005 <0.001 <0.001
U-4 pyridoxic acid
(lmol/d)
7.6±3.3 7.2±2.7 7.4±3.7 NS NS NS NS
U-Oxalate (lmol/d) 413±134 300±91 540±165 by definition <0.0001 <0.0001 <0.0001
U-Glycolate (lmol/d) 363±174 487±219 564±263 NS <0.0001 <0.0001 <0.0001
U-Urea (mmol/d) 400±114 420±103 476±151 NS NS 0.002 0.007
Blood parameters
Creatinine (lmol/l) 93.0±10.7 97.5±10.9 96.8±9.1 NS 0.01 0.015 0.008
S-pyridoxal 5P
(nmol/l)
86.0±31.0 64.9±19.7 59.6±21.2 NS <0.0001 <0.0001 <0.001
Results expressed as mean ± SD. Statistics using Mann-Whitney U test for the comparison of two groups and Kruskal-Wallis for the
comparison of three groups. NS not significant
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changes in S-pyridoxal 5P or U-4pyridoxic acid. A
small but significant decrease in mean urinary excretion
rate of glycolate after pyridoxine loading was found in
the Hyperoxalurics.
Discussion
A link between vitamin B6 and oxalate metabolism was
discovered many years ago. Primary hyperoxaluria of
type I, for instance, a genetic disease characterized by
nephrolithiasis, nephrocalcinosis, renal insufficiency as
well as systemic deposition of oxalate in various tissues
and organs other than the kidney, sometimes responds
to pharmacologic administration of vitamin B6 [10, 11,
12, 17]. Conversely, experimental depletion in vitamin
B6 also leads to hyperoxaluria and nephrocalcinosis, in
cats [18] and rats [5], where it has been amply studied.
Both observations are related to the fact that pyridoxine
is the cofactor of hepatic alanine-glyoxylate-amino-
transferase (AGT) that transaminates glyoxylate into
glycine, thus curtailing the pathway from glyoxylate to
oxalate (Fig. 1).
Idiopathic hyperoxaluria is a completely different
disease, regarded as a nutritional disorder derived ei-
ther from an excessive consumption of oxalate-con-
taining nutrients or from excessive endogenous oxalate
production from meat protein, via high hydroxyproline
and tryptophan intake. Idiopathic hyperoxaluria is
classically viewed as non-responsive to vitamin B6, at
least on a short-term basis (<3 weeks) although several
studies have suggested that pyridoxine given for longer
periods of time (6 weeks to 6 months) might be bene-
ficial to ICSF [11]. In the present study, we observed a
large scatter in the response to vitamin B6 loading,
with significant individual decreases in oxaluria (i.e.
Fig. 2 Urinary 4-pyridoxic acid and serum pyridoxal 5-phosphate
in a population of healthy subjects (controls, n=100) and recurrent
calcium stone formers without hyperoxaluria (Normooxalurics,
n=57) or with hyperoxaluria (Hyperoxalurics, n=55). Statistics
were performed using the Mann-Whitney U-test
Table 2 Correlation between 4-pyridoxic acid, pyridoxal 5-phosphate and various parameters
U-4-Pyridoxic Acid
Controls NormoOxalurics HyperOxalurics
r p r p r p
U-Creatinine +0.38 0.0001 +0.17 NS +0.42 0.002
U-Oxalate +0.21 0.03 +0.21 NS +0.25 NS
U-Glycolate +0.21 0.03 )0.09 NS +0.20 NS
Protein intake (U-Urea) +0.54 <0.0001 +0.30 0.02 +0.50 0.0002
S-Pyridoxal 5-Phosphate
Controls NormoOxalurics HyperOxalurics
r p r p r p
U-4 pyridoxic acid +0.41 <0.0001 +0.38 0.005 +0.26 NS
U-Creatinine +0.11 NS +0.15 NS +0.33 0.01
U-Oxalate +0.19 NS +0.20 NS +0.16 NS
U-Glycolate +0.05 NS +0.01 NS +0.36 0.01
Protein intake (U-Urea) +0.22 0.05 +0.10 NS +0.24 NS
Statistics using Spearman rank correlation test
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‡20%) in some subjects (three Normooxalurics, nine
Hyperoxalurics, 12 controls), a significant increase in
some others (four Normooxalurics, eight Hyperoxalu-
rics, 18 controls) and no change in most individuals;
part of this is probably due to the well-known day to
day variability of the urinary excretion rate of oxalate
on free-choice diet.
The issue as to whether or not idiopathic calcium
stone formers might have a disordered metabolism of
vitamin B6 which might account for their hyperoxal-
uria has not been systematically studied. In the early
1990s Edwards and Rose carried out a preliminary
study in eight patients selected for their high urinary
excretion rates of oxalate and glycolate. They observed
lower values of serum pyridoxal 5-phosphate after
vitamin B6 loading in some patients than in a control
population, particularly in patients who had a good
response of urinary oxalate to vitamin B6. For some
reason these patients became very rare and the
study was therefore interrupted (A. Rose, personal
communication). To the best of our knowledge, these
are the only data available on this aspect of the subject
so far.
Most idiopathic calcium stone formers have serum
levels of pyridoxal 5 phosphate, the active moiety of
vitamin B6, in the normal range. However, the present
study shows that mean serum levels are lower in pa-
tients than in controls, not only due to very low values
in some patients but also to an overall shift in the
distribution of that parameter in the patient popula-
tion. In other words, ICSF do not activate pyridoxine
into pyridoxal 5-phosphate to the same extent as
healthy subjects do, either on a physiological or on a
pharmacological intake of pyridoxine, and this is ob-
served independently of the oxaluric status of the pa-
tients. There was no relationship between serum levels
of pyridoxal 5-phosphate and urinary oxalate excre-
tion.
It has been postulated in the past [19] that this lack
of activation of pyridoxine might simply reflect an
insufficient intake and/or absorption of the vitamin.
However, the fact that the excretion rate of 4-pyri-
doxic acid is similar in patients and in controls, both
before and after vitamin B6 loading, rules out this
hypothesis. This is in agreement with Tiselius et al.,
who measured the urinary excretion of 4-Pyridoxic
acid and oxalic acid in 75 patients with urinary calculi
and in 50 normal subjects on regular diet and who
found that most patients had a normal 4-Pyridoxic
acid excretion [20].
Explanations to account for the present findings so
far are either an insufficient activation of pyridoxine
into Pyridoxal 5P or an excessive catabolism of Pyri-
doxal 5P. The exact site where the phenomenon occurs
and the precise mechanism whereby it takes place re-
main to be elucidated. What is currently known is that
Table 3 Characteristics, blood and urinary data of the subjects before and after pyridoxine loading
Group p values
Controls
(n=50)
NormoOxalurics
(n=15)
HyperOxalurics
(n=40)
Normo- vs.
HyperOxalurics
Normo-Oxalurics
vs. controls
HyperOxalurics vs.
controls
Age (y)
Height (m)
Weight (kg)
BMI (kg/m2)
37.4±10.9
1.79±0.07
75.2±11.3
23.6±3.6
55.0±8.8
1.75±0.06
79.7±11.6
26.2±3.9
50.8±12.5
1.75±0.07
82.2±11.6
27.1±3.9
NS
NS
NS
NS
<0.0001
NS
NS
0.006
<0.0001
0.02
0.003
<0.0001
U-Volume
(ml/d)
baseline
after B6
1826±673
1887±791
2285±631
2205±687
1961±681
2112±672
NS
NS
0.02
NS
NS
NS
U-Creatinine
(lmol/d)
baseline
after B6
14122±2817
13434±3354
13137±2495
14066±2685
15012±3225
14924±3492
NS
NS
NS
NS
NS
NS
U-Oxalate
(lmol/d)
baseline
after B6
loading
385±107
412±125
419±92
419±103
501±182
508±191
NS
NS
NS
NS
0.0001
0.01
U-Glycolate
(lmol/d)
baseline
after B6
415±186
409±205
440±103
427±102
521±218
483±196*
NS
NS
NS
NS
0.007
NS
U-4 pyridoxic
acid (lmol/d)
baseline
after B6
9.0±10.5
862±323**
6.4±2.3
1003±226**
8.4±5.3
857±354**
NS
NS
NS
NS
NS
NS
S-pyridoxal
5P (nmol/l)
baseline
after B6
80.0±27.4
546±180**
63.3±20.6
429±115**
60.1±21.8
415±180**
NS
NS
0.04
0.04
0.004
0.001
Results expressed as mean ± SD. Statistics using Mann-Whitney U test for intergroup comparison and Wilcoxon paired test for
intragroup comparison.
*p £ 0.03 vs. baseline, **p £ 0.001 vs. baseline
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(1) the absorption of different dietary forms of vitamin
B6 (i.e. pyridoxine, pyridoxine-glucosides and pyri-
doxamine) is influenced by microbial and mucosal
enzymes at the level of intestine [21] and (2) transfor-
mation of pyridoxine into pyridoxal 5-phosphate
requires pyridoxine oxidase, pyridoxalkinase-phospha-
tase and vitamin B2 in the liver. It remains to be seen,
however, whether one component of the biochemical
pathway is altered.
Clearly, stone formers have a higher protein intake
than healthy volunteers, thus having a large require-
ments for vitamin B6 [15]. This might have led S-pyri-
doxal 5P to decrease via catabolism. In fact, this
explanation does not hold true because of the observed
positive, not negative, correlation between S-pyridoxal
5P and U-urea, but in the controls only. This is prob-
ably due to the presence of significant amounts of vita-
min B6 in meat, fish and poultry.
Finally, although low levels of the active metabolite
of vitamin B6 are sometimes observed in idiopathic
calcium stone formers, the present study does not pro-
vide evidence for a cause and effect relationship with
hyperoxaluria, contrary to what had been postulated so
far. This points to the fact that other important factors
do influence urinary oxalate excretion, in particular the
calcium to oxalate ratio in the diet.
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